CLCGY:OTO-Clicks Group Ltd ADR (Sponsored) (USD)

COMMON STOCK | Pharmaceutical Retailers | OTC Pink

Last Closing

USD 39.66

Change

+0.31 (+0.79)%

Market Cap

USD 2.38B

Volume

1.10K

Analyst Target

N/A
Analyst Rating

Verdict

ducovest Verdict

Verdict

About

Clicks Group Ltd is engaged in retail sale and supply of healthcare and beauty products in southern Africa. It offers health, beauty and lifestyle products to women in the middle to upper income markets.

Unadjusted Closing Price

Adjusted Closing Price

Share Volume

Relative Performance (Total Returns)

Compare
Relative Returns (From:    To: 2024-12-26 )

Largest Industry Peers for Pharmaceutical Retailers

Symbol Name Price(Change) Market Cap
JDHIY JD Health International Inc

N/A

USD 12.19B
JDHIF JD Health International Inc

N/A

USD 10.00B
ALBHF Alibaba Health Information Tec..

-0.01 (-3.26%)

USD 8.29B
RADLY Raia Drogasil SA ADR

-0.10 (-2.67%)

USD 7.12B
SHPPF Shop Apotheke Europe N.V

N/A

USD 3.20B
SAEYY Shop Apotheke Europe N.V

N/A

USD 2.88B
NOTR Nowtransit Inc

N/A

USD 0.55B
ZRSEF Zur Rose Group AG

-15.17 (-38.86%)

USD 0.46B
PNPL Pineapple Express

N/A

USD 0.01B
RLLVF Relevium Technologies Inc

N/A

USD 5.33M

ETFs Containing CLCGY

N/A

Market Performance

  Market Performance vs. Industry/Classification (Pharmaceutical Retailers) Market Performance vs. Exchange (OTC Pink)
  Value Sector Median Percentile Rank Grade Market Median Percentile Rank Grade
YTD  
Capital Gain 11.88% 93% A 68% D+
Dividend Return 2.13% 100% F 26% F
Total Return 14.00% 93% A 67% D+
Trailing 12 Months  
Capital Gain 13.25% 93% A 69% C-
Dividend Return 2.15% 100% F 26% F
Total Return 15.40% 93% A 68% D+
Trailing 5 Years  
Capital Gain 8.54% 100% F 69% C-
Dividend Return 9.42% 100% F 25% F
Total Return 17.96% 100% F 65% D
Average Annual (5 Year Horizon)  
Capital Gain 5.87% 46% F 47% F
Dividend Return 7.94% 50% F 46% F
Total Return 2.07% 100% F 46% F
Risk Return Profile  
Volatility (Standard Deviation) 24.67% 92% A 80% B-
Risk Adjusted Return 32.19% 83% B 68% D+
Market Capitalization 2.38B 80% B- 86% B+

Annual Financials (USD)

Quarterly Financials (USD)

Analyst Rating

Target Price Action Rating Action Analyst Rating Price Date

This is a composite scorecard based on the application of evaluation criteria deemed most important by analysts. This is not a buy or sell recommendation.

What to like:
Superior risk adjusted returns

This stock has performed well, on a risk adjusted basis, compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile.

Superior return on assets

The company management has delivered better return on assets in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior capital utilization

The company management has delivered better return on invested capital in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior return on equity

The company management has delivered better return on equity in the most recent 4 quarters than its peers, placing it in the top quartile.

Superior total returns

The stock has outperformed its sector peers on average annual total returns basis in the past 5 years (for a hold period of at least 12 months) and is in the top quartile.

Low volatility

The stock’s annual returns have been stable and consistent compared to its sector peers(for a hold period of at least 12 months) and is in the top quartile. Although stability is good, also keep in mind it can limit returns.

High market capitalization

This is one of the largest entities in its sector and is among the top quartile. Such companies tend to be more stable.

Positive cash flow

The company had positive total cash flow in the most recent four quarters.

Positive free cash flow

The company had positive total free cash flow in the most recent four quarters.

What to not like:
Overpriced on cashflow basis

The stock is trading high compared to its peers on a price to cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Overpriced compared to book value

The stock is trading high compared to its peers median on a price to book value basis.

Below median dividend returns

The company’s average income yield over the past 5 years has been low compared to its peers. However, it is not a problem if you are not looking for income.

Overpriced on free cash flow basis

The stock is trading high compared to its peers on a price to free cash flow basis. It is priced above the median for its sectors. Proceed with caution if you are considering to buy.

Low Earnings Growth

This stock has shown below median earnings growth in the previous 5 years compared to its sector

Low Revenue Growth

This stock has shown below median revenue growth in the previous 5 years compared to its sector